MoonLake Immunotherapeutics

1. Sonelokimab HS topline2H 2026Sonelokimab HS topline, 2H 2026, material
2. Sonelokimab PsA enrollment done3Q 2026Sonelokimab PsA enrollment done, 3Q 2026, routine
3. Sonelokimab PPP Ph3 start2H 2026Sonelokimab PPP Ph3 start, 2H 2026, routine
4. Sonelokimab HS BLA filingSep 2026Sonelokimab HS BLA filing, Sep 2026, notable
5. Sonelokimab PsA topline4Q 2026Sonelokimab PsA topline, 4Q 2026, material
6. Sonelokimab HS PDUFA dateNov 2026Sonelokimab HS PDUFA date, Nov 2026, thesis-defining
7. Sonelokimab axSpA interimEnd 2026 / early 2027Sonelokimab axSpA interim, End 2026 / early 2027, notable
8. Sonelokimab PsA readout1H 2027Sonelokimab PsA readout, 1H 2027, notable
9. Hercules Loan Tranche 3 corporateMar 15, 2027Hercules Loan Tranche 3 corporate, Mar 15, 2027, routine
10. Sonelokimab HS commercial launch2H 2027Sonelokimab HS commercial launch, 2H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.